n the pursuit of a sustainable future, the healthcare sector faces the critical challenge of integrating environmental responsibility with its core mission of patient care and innovation. This challenge was a central theme of the first article in this series, Sustainable Healthcare: Balancing Patient Care and Environmental Impact, an exploration into how the biotechnology and pharmaceutical industry is navigating this complex landscape.

The Challenge: Climate Change and the Medicine Life Cycle

Climate change is no longer a future threat; it is a present reality, changing the intricate healthcare ecosystem and global medicine life cycle. From altering disease patterns to impacting clinical trials, manufacturing, and ultimately patient access, the effects are pervasive and profound. A comprehensive Lancet Planetary Health report outlines how rising temperatures and extreme weather events are shifting the geographical distribution of infectious diseases, increasing respiratory illnesses, and exacerbating noncommunicable diseases, creating an urgent and evolving public health crisis. Simultaneously, the healthcare sector itself is a significant contributor to global greenhouse gas emissions, responsible for an estimated 4.4% of worldwide emissions. The pharmaceutical industry, in particular, carries a heavy Scope 3 emissions burden, stemming from its complex global supply chains and energy-intensive manufacturing processes.

The European Commission (EC) has helped power the European Union’s (EU’s) proactive stance through sustainability initiatives like the European Green Deal and the substantial funding available via Horizon Europe. These policies are fostering a growing ecosystem of support for sustainable R&D and manufacturing, evidenced by pioneering projects like Eternal and Impactive. “Sustainable pharma production technologies are essential but complex,” explained Tomasz Dylag (EC). “They require systemic adaptation from early research through to regulation.” This underscores the monumental task at hand, requiring a cohesive, multifaceted approach.

Addressing the Challenge: EMA’s Actions on Sustainability and Preparedness

The scale of the climate crisis demands a commensurate response. Addressing the pharmaceutical sector’s environmental footprint and building resilience against climate-induced disruptions promises substantial global impact. While precise long-term economic and health benefits are complex to quantify, credible estimates suggest that mitigating climate change could prevent millions of premature deaths globally, reduce the burden on healthcare systems, and safeguard trillions in economic losses. For instance, the World Health Organization estimates that between 2030 and 2050, climate change is expected to cause approximately 250,000 additional deaths per year from malnutrition, malaria, diarrhea, and heat stress, a burden that may be significantly reduced through concerted action.

The EMA is a leading voice in the EU on both addressing the threat from climate change and enabling a more sustainable future for medicines, working in partnership with other regulators. Climate change imperils public health both through the increase in infectious and respiratory diseases, and the very infrastructure that delivers safe and effective medicines. The EMA is actively engaged on both fronts, diligently monitoring the evolving health landscape, for example, through its working groups on antimicrobial resistance and emerging threats, and proactively enabling sustainable practices across the entire medicine life cycle.

The EMA is also spearheading initiatives to bolster the resilience of the medicine supply chain against climate-induced instability. This includes enhancing its pharmacovigilance systems to detect and respond to medicine shortages more effectively, as extreme weather events can disrupt manufacturing and distribution. Furthermore, the agency is exploring ways to support diversified supply chains and foster local manufacturing capabilities where appropriate, reducing reliance on single-source origins vulnerable to climate shocks.

Regulatory Flexibility for Sustainable Innovation
A cornerstone of the EMA’s strategy is modernizing regulatory frameworks to facilitate sustainable innovation. This involves a commitment to streamlining processes, thereby freeing up crucial capacity for advancements. “As regulators, we must monitor, share information, and simplify processes to free resources, allowing more time and capacity for innovation,” Jekerle emphasized. This forward-thinking approach aims to remove regulatory bottlenecks that might otherwise hinder the adoption of greener manufacturing technologies and sustainable product development.

Leading by Example: EMA’s Internal Sustainability
EMA is committed to “leading by example” through its own internal sustainability practices. The agency has achieved environmental certification, reflecting its dedication to minimizing its operational footprint. This internal commitment reinforces its external advocacy for sustainability within the broader pharmaceutical ecosystem.

Leading by Example: More than Compliance
EMA’s approach extends beyond mere compliance; it aims to be a catalyst for systemic change. The agency recognizes that providing regulatory clarity and flexibility is paramount to scaling up low-carbon technologies and practices within the pharmaceutical industry. The EMA is actively embedding sustainability considerations into the core benefit-risk paradigm of medicinal products, rather than treating it as an isolated afterthought. This holistic view aligns seamlessly with themes discussed in our previous sustainability articles (on reducing greenhouse gas emissions and building partnerships for environmental sustainability), which advocate for comprehensive, life-cycle decision-making that meticulously balances patient safety, innovation, and environmental impact.

Regulation as an Enabler of Sustainability

In essence, the EMA is not merely adapting to the challenges posed by climate change; it is actively shaping a future where sustainable healthcare is the default, not an exception. With the right frameworks in place, sustainability transforms from a perceived burden into a clear pathway towards smarter, more resilient, and more responsible healthcare.

For readers and other stakeholders looking to contribute to this critical effort, engagement can take many forms. Pharmaceutical companies are encouraged to proactively engage with EMA on sustainable drug development initiatives, participate in pilot programs, and share best practices. Researchers can focus on developing novel, low-carbon manufacturing processes and environmentally friendly excipients. Healthcare professionals can advocate for greener practices within their institutions and consider the environmental impact of prescribing patterns. Policymakers and other regulatory agencies can draw lessons from the EMA’s proactive stance, considering how similar regulatory flexibility and sustainability integration can be implemented within their own remits.

However, success is not without its barriers. The pharmaceutical industry’s global supply chains and existing infrastructure present significant challenges to achieving rapid decarbonization. Furthermore, harmonizing regulatory approaches across different regions remains crucial to avoid creating new barriers to sustainable innovation. The EMA’s initiative requires continued support in terms of dedicated resources, collaborative partnerships with industry and academia, and ongoing dialogue with other global regulatory bodies to foster a unified approach. By sharing experiences and lessons learned, other regulatory agencies can indeed consider adopting similar frameworks, emphasizing regulatory flexibility, internal sustainability, and the integration of environmental impact into core benefit-risk assessments. EMA’s journey provides a compelling blueprint for how regulation can truly serve as an enabler of a sustainable future for medicines.